These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 11361553)
1. Liposomal drug targeting in the treatment of Kaposi's sarcoma. Wernz JC AIDS Patient Care STDS; 1996 Dec; 10(6):362-7. PubMed ID: 11361553 [No Abstract] [Full Text] [Related]
2. Liposomal daunorubicin is not recommended in patients with less than advanced HIV-related Kaposi's sarcoma. White RM AIDS; 1997 Sep; 11(11):1412-3. PubMed ID: 9302461 [No Abstract] [Full Text] [Related]
3. Liposomal daunorubicin marketed for HIV-related Kaposi's sarcoma. Am J Health Syst Pharm; 1996 Jul; 53(13):1500, 1505. PubMed ID: 8809269 [No Abstract] [Full Text] [Related]
4. Pharmacology of liposomal daunorubicin and its use in Kaposi's sarcoma. Chew T; Jacobs M Oncology (Williston Park); 1996 Jun; 10(6 Suppl):28-33; discussion 37-8. PubMed ID: 16871707 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. Hjortsberg C; Persson U; Lidbrink E; Bennett C Acta Oncol; 1999; 38(8):1063-7. PubMed ID: 10665764 [TBL] [Abstract][Full Text] [Related]
6. Kaposi's sarcoma: DaunoXome approved. AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485 [TBL] [Abstract][Full Text] [Related]
8. Liposomal anthracycline chemotherapy and the risk of second malignancies in patients with Kaposi's sarcoma (KS). Bendle M; Pealing J; Papanastasopoulos P; Bower M Cancer Chemother Pharmacol; 2014 Sep; 74(3):611-5. PubMed ID: 25055936 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi's sarcoma. Girard PM; Bouchaud O; Goetschel A; Mukwaya G; Eestermans G; Ross M; Rozenbaum W; Saimot AG AIDS; 1996 Jun; 10(7):753-7. PubMed ID: 8805866 [TBL] [Abstract][Full Text] [Related]
10. FDA approves DaunoXome as first-line therapy for Kaposi's sarcoma. Food and Drug Administration. J Int Assoc Physicians AIDS Care; 1996 May; 2(5):50-1. PubMed ID: 11363534 [TBL] [Abstract][Full Text] [Related]
11. Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi's sarcoma: a report of four cases. Cabriales S; Bresnahan J; Testa D; Espina BM; Scadden DT; Ross M; Gill PS Oncol Nurs Forum; 1998; 25(1):67-70. PubMed ID: 9460774 [TBL] [Abstract][Full Text] [Related]
12. Treatment of classic Kaposi's sarcoma with liposomal encapsulated doxorubicin. Gottlieb JJ; Washenik K; Chachoua A; Friedman-Kien A Lancet; 1997 Nov; 350(9088):1363-4. PubMed ID: 9365453 [No Abstract] [Full Text] [Related]
13. Randomized cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. Uthayakumar S; Bower M; Money-Kyrle J; Muyshondt C; Youle M; Hannon F; Phillips R; Gazzard BG; Boag F AIDS; 1996 May; 10(5):515-9. PubMed ID: 8724043 [TBL] [Abstract][Full Text] [Related]
14. DaunoXome approved. AIDS Patient Care STDS; 1996 Aug; 10(4):263. PubMed ID: 11361607 [No Abstract] [Full Text] [Related]